Evolution Research Group (ERG) is an independent clinical research site company based in New Providence, NJ; it focuses on neuroscience and special populations. Acquiring Richmond Behavioral Associates (RBA), a Staten Island, NY clinical trial organization, will enable the firm to broaden its capabilities, covering both adult and pediatric populations.
Andria Chastain, COO for ERG, said taking on RBA will enable the company to expand its footprint in the New York region. Of RBA, she said, “Their history of delivering quality results in complex outpatient trials, particularly in children and adolescents, expands our capacity.”
Chastain added that the acquisition complements the capabilities of its various teams, including its inpatient pediatric pharmacokinetics unit.
Adam Smith, an investigator with RBA, said, “The opportunity for growth and expansion in our geographic region is undeniable and, given ERG's excellent reputation in the industry and their proven track record of growing portfolio sites, our investigators…firmly believe that ERG is the perfect partner to take our site to the next level."
Michael Farah, ERG chairman and partner at Linden Capital Partners, said RBA has a strong strategic growth plan, which will enable his firm to “further service our deep client base and continue to assist in the development of important new therapies."